Cargando…

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement

Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and compare it with that of vancomycin over a 3-mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Somolinos, Mar, Díaz-Navarro, Marta, Benjumea, Antonio, Matas, José, Vaquero, Javier, Muñoz, Patricia, Sanz-Ruíz, Pablo, Guembe, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525811/
https://www.ncbi.nlm.nih.gov/pubmed/37760741
http://dx.doi.org/10.3390/antibiotics12091445
_version_ 1785110873683001344
author Sánchez-Somolinos, Mar
Díaz-Navarro, Marta
Benjumea, Antonio
Matas, José
Vaquero, Javier
Muñoz, Patricia
Sanz-Ruíz, Pablo
Guembe, María
author_facet Sánchez-Somolinos, Mar
Díaz-Navarro, Marta
Benjumea, Antonio
Matas, José
Vaquero, Javier
Muñoz, Patricia
Sanz-Ruíz, Pablo
Guembe, María
author_sort Sánchez-Somolinos, Mar
collection PubMed
description Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and compare it with that of vancomycin over a 3-month period. We designed an in vitro model in which we calculated the percentage reduction in log cfu/mL counts of sonicated steel discs contaminated with staphylococci and further exposed to bone cement discs loaded with 2.5% or 5% vancomycin and dalbavancin at various timepoints (24 h, 48 h, 1 week, 2 weeks, 6 weeks, and 3 months). In addition, we tested the anti-biofilm activity of eluted vancomycin and dalbavancin at each timepoint based on a 96-well plate model in which we assessed the percentage reduction in metabolic activity. We observed a significant decrease in the dalbavancin concentration from 2 weeks of incubation, with sustained anti-biofilm activity up to 3 months. In the case of vancomycin, we observed a significant decrease at 1 week. The concentration gradually increased, leading to significantly lower anti-biofilm activity. The percentage reduction in cfu/mL counts was higher for dalbavancin than for vancomycin at both the 2.5% and the 5% concentrations. The reduction in log cfu/mL counts was higher for S. epidermidis than for S. aureus and was particularly more notable for 5% dalbavancin at 3 months. In addition, the percentage reduction in metabolic activity also decreased at 3 months in 5% dalbavancin and 5% vancomycin, with more notable values recorded for the latter.
format Online
Article
Text
id pubmed-10525811
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105258112023-09-28 In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement Sánchez-Somolinos, Mar Díaz-Navarro, Marta Benjumea, Antonio Matas, José Vaquero, Javier Muñoz, Patricia Sanz-Ruíz, Pablo Guembe, María Antibiotics (Basel) Article Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and compare it with that of vancomycin over a 3-month period. We designed an in vitro model in which we calculated the percentage reduction in log cfu/mL counts of sonicated steel discs contaminated with staphylococci and further exposed to bone cement discs loaded with 2.5% or 5% vancomycin and dalbavancin at various timepoints (24 h, 48 h, 1 week, 2 weeks, 6 weeks, and 3 months). In addition, we tested the anti-biofilm activity of eluted vancomycin and dalbavancin at each timepoint based on a 96-well plate model in which we assessed the percentage reduction in metabolic activity. We observed a significant decrease in the dalbavancin concentration from 2 weeks of incubation, with sustained anti-biofilm activity up to 3 months. In the case of vancomycin, we observed a significant decrease at 1 week. The concentration gradually increased, leading to significantly lower anti-biofilm activity. The percentage reduction in cfu/mL counts was higher for dalbavancin than for vancomycin at both the 2.5% and the 5% concentrations. The reduction in log cfu/mL counts was higher for S. epidermidis than for S. aureus and was particularly more notable for 5% dalbavancin at 3 months. In addition, the percentage reduction in metabolic activity also decreased at 3 months in 5% dalbavancin and 5% vancomycin, with more notable values recorded for the latter. MDPI 2023-09-13 /pmc/articles/PMC10525811/ /pubmed/37760741 http://dx.doi.org/10.3390/antibiotics12091445 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sánchez-Somolinos, Mar
Díaz-Navarro, Marta
Benjumea, Antonio
Matas, José
Vaquero, Javier
Muñoz, Patricia
Sanz-Ruíz, Pablo
Guembe, María
In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
title In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
title_full In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
title_fullStr In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
title_full_unstemmed In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
title_short In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
title_sort in vitro efficacy of dalbavancin as a long-acting anti-biofilm agent loaded in bone cement
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525811/
https://www.ncbi.nlm.nih.gov/pubmed/37760741
http://dx.doi.org/10.3390/antibiotics12091445
work_keys_str_mv AT sanchezsomolinosmar invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT diaznavarromarta invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT benjumeaantonio invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT matasjose invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT vaquerojavier invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT munozpatricia invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT sanzruizpablo invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement
AT guembemaria invitroefficacyofdalbavancinasalongactingantibiofilmagentloadedinbonecement